Open access · OA
via OpenAlex
Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin
Andrew J. Armstrong, Daniel J. George, Susan Halabi
Journal of Clinical Oncology · 2012 · ▲ 156 citations
Abstract
PURPOSE: Lactate dehydrogenase (LDH) is an enzyme involved in anaerobic glycolysis and regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR)-containing complex 1 (PI3K/Akt/TORC1) pathway as well as tumor hypoxia/necrosis. High serum LDH levels are associated with poor prognosis in patients with cancer, including renal cell carcinoma (RCC). We tested whether serum LDH is prognostic and has predictive value in patients with metastatic RCC receiving an mTOR inhibitor. PATIENTS AND METHODS: We evaluated pretreatment and post-treatment serum LDH in 404 poor-risk patients with RCC treated with the TORC1 inhibitor temsirolimus or interferon alfa in an international phase III randomized trial. The proportional hazards model was used to test for the prognostic and predictive association of LDH in predicting overall survival (OS). RESULTS: Mean baseline serum normalized LDH was 1.23 times the upper limit of normal (ULN; range, 0.05 to 28.5 × ULN). The multivariable hazard ratio for death was 2.81 (95% CI, 2.01 to 3.94; P < .001) for patients with LDH more than 1 × ULN versus patients with LDH ≤ 1 × ULN. The LDH-treatment interaction term was statistically significant for OS (P = .016). Among 140 patients with LDH above the ULN, OS was significantly improved with temsirolimus (6.9 v 4.2 months; P < .002). Among 264 patients with normal LDH, OS was not significantly improved with temsirolimus as compared with interferon therapy (11.7 v 10.4 months; P = .514). CONCLUSION: Serum LDH is a prognostic and a predictive biomarker for the survival benefit conferred by TORC1 inhibition in poor-risk RCC. Further investigation of the predictive role of LDH as a measure of benefit with PI3K/TORC1 pathway inhibition in other RCC risk groups and other tumor types is warranted.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1200/jco.2011.40.9631
- Canonical
- link ↗
- Fetched
- 2026-08-24 MST
Cite this
APA
Armstrong, A.J., George, D.J., & Halabi, S. (2012). Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin. <em>Journal of Clinical Oncology</em>. https://doi.org/10.1200/jco.2011.40.9631
Vancouver
Armstrong AJ, George DJ, Halabi S. Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin. Journal of Clinical Oncology. 2012. doi:10.1200/jco.2011.40.9631.
BibTeX
@article{andrew2012SerumL,
title = {Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin},
author = {Andrew J. Armstrong and Daniel J. George and Susan Halabi},
journal = {Journal of Clinical Oncology},
year = {2012},
doi = {10.1200/jco.2011.40.9631},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Reports 2020
Open access · CC-BY
NAD+ Repletion Rescues Female Fertility during Reproductive Aging
Biotechnology Journal 2024
Open access · CC-BY
Evaluation of NAD+ precursors for improved metabolism and productivity of antibody‐producing CHO cell
Cell Biochemistry and Biophysics 2026
Citation only
RNA-Based Biological Age Clocks Track Chronological Age in Skeletal Muscle but Show Limited Discrimination of Sarcopenia
Bispebjerg Hospital 2025
Open access · US-GOV
Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibility Study
Bispebjerg Hospital 2026
Open access · US-GOV
Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Randomized Controlled Trial
Journal of Assisted Reproduction and Genetics 2024
Open access · CC-BY